RO 📈 Roche Holding - Overview
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012032113
RO: Medicines, Diagnostic Tests, Instruments, Digital Health Solutions
Rocher Holding AG is a Swiss multinational healthcare company that operates globally, with a presence in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company's pharmaceutical division develops and commercializes a wide range of medicines in various therapeutic areas, including anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune diseases, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Rocher's pharmaceutical portfolio includes both established brands and innovative new treatments, with a focus on improving patient outcomes and addressing unmet medical needs. The company is also committed to investing in research and development, with a pipeline of promising new products in various stages of development.
In addition to its pharmaceutical business, Roche Holding AG is a leading provider of in vitro diagnostics, offering a broad range of tests and instruments for the diagnosis of various diseases, including cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other conditions. The company's diagnostic solutions are designed to provide accurate and reliable results, enabling healthcare professionals to make informed treatment decisions.
Rocher's diagnostic portfolio also includes digital health solutions, which leverage advanced technologies such as artificial intelligence and machine learning to improve patient care and outcomes. These solutions include data analytics platforms, remote monitoring systems, and other digital tools that support personalized medicine and precision healthcare.
Founded in 1896, Roche Holding AG is headquartered in Basel, Switzerland, and has a long history of innovation and excellence in the healthcare industry. Today, the company is a global leader in pharmaceuticals and diagnostics, with a commitment to improving lives and transforming healthcare.
Additional Sources for RO Stock
RO Stock Overview
| Market Cap in USD | 229,924m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Industry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception |
RO Stock Ratings
| Growth 5y | 6.36% |
| Fundamental | 72.8% |
| Dividend | 61.4% |
| Rel. Performance Sector | -0.31 |
| Analysts | - |
| Fair Price Momentum | 259.73 CHF |
| Fair Price DCF | 4262.74 CHF |
RO Dividends
| Dividend Yield 12m | 3.59% |
| Yield on Cost 5y | 3.75% |
| Annual Growth 5y | 1.77% |
| Payout Consistency | 100.00% |
RO Growth Ratios
| Growth Correlation 3m | -39.8% |
| Growth Correlation 12m | 72.6% |
| Growth Correlation 5y | -21% |
| CAGR 5y | 0.85% |
| CAGR/Mean DD 5y | 0.05 |
| Sharpe Ratio 12m | 0.11 |
| Alpha | -8.33 |
| Beta | 0.28 |
| Volatility | 19.52% |
| Current Volume | 22k |
| Average Volume 20d | 43.2k |
As of December 05, 2024, the stock is trading at CHF 267.40 with a total of 21,972 shares traded.
Over the past week, the price has changed by -0.22%, over one month by -9.78%, over three months by -11.52% and over the past year by +6.39%.
Yes, based on ValueRay Fundamental Analyses, Roche Holding (SW:RO) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 72.84 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RO as of December 2024 is 259.73. This means that RO is currently overvalued and has a potential downside of -2.87%.
Roche Holding has no consensus analysts rating.
According to ValueRays Forecast Model, RO Roche Holding will be worth about 281.1 in December 2025. The stock is currently trading at 267.40. This means that the stock has a potential upside of +5.12%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 286 | 7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 281.1 | 5.1% |